Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADI-270 · 1 trial · 1 indication
This primary endpoint will be used to determine the Maximum Tolerated Dose (MTD) or Maximum Assessed dose (MAD)
This primary endpoint will be used to determine the MTD/MAD of ADI-270
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | ADI-270 is administered at ascending dose levels as a single dose to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD) of ADI-270 |
| Dose Expansion | EXPERIMENTAL | Dose Expansion with ADI-270 at the MTD/MAD to confirm recommended phase 2 dose (Part 2). |
| Name | Type | Description |
|---|---|---|
| ADI-270 | DRUG | Anti-CD70 CAR-T |
| Fludarabine | DRUG | Chemotherapy for Lymphodepeletion |
| Cyclophosphamide | DRUG | Chemotherapy for Lymphodepletion |
Inclusion Criteria: 1. Histologically or cytologically confirmed clear cell RCC 2. Documented evidence of advanced or metastatic diseases. 3. Patients must have been treated with an immune checkpoint inhibitor and a VEGF inhibitor (the VEGF inhibitor must have been administered in the advanced and/...
ADI-270 is an investigational small molecule being developed for the treatment of Clear Cell Renal Cell Carcinoma (ccRCC). It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug has received Fast Track designation from the FDA.
ADI-270 is being developed by Adicet Bio, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ACET. The company is conducting clinical trials for this investigational drug in the United States.
ADI-270 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA. The drug has received Fast Track designation, which is intended to expedite the development and review of therapies for serious conditions.
ADI-270 is being studied in a Phase 1/2 clinical trial with the identifier NCT06480565. This trial is active but not recruiting participants, with an estimated enrollment of 60 patients. The study is being conducted in the United States and includes adults aged 18 years and older.
No, ADI-270 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The FDA has granted Fast Track designation to ADI-270 for the treatment of Clear Cell Renal Cell Carcinoma, which may expedite its development and review process.